Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les ...

The best Delta-8 gummies are third-party lab tested, accurately dosed, and use clean extraction from hemp—not synthetic ...

A NEW PUBLICATION IN THE SCIENTIFIC JOURNAL PLOS ONE, SHOWS THAT MASITINIB CAN LOWER SERUM NEUROFILAMENT LIGHT CHAIN, AN IMPORTANT BIOMARKER FOR NEURODEGENERATIVE DISORDERS, INCLUDING MULTIPLE ...

As healthcare systems around the world seek faster, more accurate, and decentralized testing solutions, Anbio is well-positioned to meet this demand through a diversified portfolio and expanding ...

KUALA LUMPUR, MALAYSIA, May 15, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative ...

Audien has quickly emerged as a category leader in the OTC hearing aid market by developing sleek, nearly invisible in-ear ...

Explore NovaaLab’s FDA-cleared red light therapy devices, supported by clinical studies, and designed to help reduce pain, improve recovery, and support wellness — all from the comfort of home. Salt ...

Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug exclusive approval from U.S.

Following completion of the dose escalation phase in relapsed/refractory acute leukemia patients with FLT3 mutations, Biomea ...

Sight Sciences’ management is scheduled to present on Tuesday, May 27, 2025, at 09:00 am PT / 12:00 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the ...

Alumis received an upfront license fee of $20.0 million in March 2025 and will receive an additional $20.0 million in near-term co-development payments, with potential for additional milestone ...

SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life ...